![]() |
Speaking of Mol BioAuthor: Thermo Fisher Scientific
Speaking of Mol Bio, a podcast series from Thermo Fisher Scientific, discusses trending applications in science and the molecular biology aspects of those applications. Our host delves in to deep discussion with CEOs, R&D scientists, researchers, and key opinion leaders across the globe. Speaking of Mol Bio helps scientific curious people - from all scientific and non-scientific backgrounds - understand how modern molecular biology applications can help push the boundaries in medicine, science, drug discovery, and in the cure and treatment of diseases. Music from NOWHERE by ikson (https://www.iksonmusic.com) Language: en Genres: Life Sciences, Natural Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it Trailer: |
Listen Now...
DNA-encoded library use in living cells for drug discovery
Episode 3
Wednesday, 22 April, 2026
In this episode of Speaking of Mol Bio, host Steve Lewis speaks with Dr. Leif Larsen, Director of Biology at Vipergen, about the power of DNA-encoded libraries (DELs) in modern drug discovery. DEL technology enables researchers to screen extremely large chemical libraries by attaching a unique DNA barcode to each compound, allowing millions, or even hundreds of millions, of compounds to be analyzed simultaneously through sequencing. Larsen explains how Vipergen’s platform flips traditional screening methods by storing massive compound libraries in a single tube and identifying binding interactions through DNA sequencing. He also describes their proprietary Binder Trap Enrichment (BTE) method, which links DNA barcodes when compounds successfully bind their protein targets. One of the company’s most innovative advances is performing DEL screening inside living Xenopus oocytes. By expressing target proteins in these large cells and microinjecting DNA-encoded libraries, researchers can evaluate binding events in a physiologically relevant environment. The discussion also explores how this technology accelerates early drug discovery timelines and enables screening of difficult targets such as transcription factors and membrane proteins. Larsen closes by highlighting emerging areas such as PROTAC-based targeted protein degradation and how DEL screening can help identify molecules suitable for these next-generation therapeutic strategies. Subscribe to get future episodes as they drop and if you like what you’re hearing we hope you’ll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.












